Planegg/Martinsried, May 30, 2023. Medigene AG , an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, will participate at the BIO. | May 30, 2023
Planegg/Martinsried, May 22, 2023. Medigene AG , an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, announced today that the. | May 22, 2023
Planegg/Martinsried, May 8, 2023. Medigene AG , an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, will present at the following. | May 8, 2023
Medigene accelerates the expansion of its end-to-end platform of multiple, combinable, exclusive and proprietary technologies with the potential to create best-in-class T cell receptor engineered T. | May 2, 2023